Multidisciplinary team meetings significantly impact pancreatic cancer care

Evidence from 36 studies reveals that multidisciplinary team meetings (MDMs) for pancreatic cancer significantly affect care decisions, influencing initial diagnoses in 3.4%-21.7% of cases and altering treatment plans in 18.2%-72.2%. These meetings improve clinical trial participation but incur substantial preparation time (16.5 hours weekly) and financial costs ($240 per case). Best practices suggest standardization and leveraging emerging technologies to enhance data collection and patient identification for clinical trials, highlighting the critical need for cost-effective workflows.